Home Geriatric Medicine Falls, Gait and Balance Disorders

Falls, Gait and Balance Disorders

๐Ÿ“‹ Key Information Summary

๐Ÿ“‹
  • Falls are a major geriatric syndrome affecting approximately 30% of community-dwelling Australians aged โ‰ฅ65 years each year, rising to 50% in those aged โ‰ฅ80 years; they are the leading cause of injury-related hospitalisation and death in older Australians.
  • Multifactorial risk assessment is the cornerstone of falls prevention โ€” always evaluate gait, balance, muscle strength, vision, cognition, medications, continence, orthostatic hypotension, footwear and home environment.
  • Gait and balance examination should include the Timed Up and Go (TUG) test, 30-Second Chair Stand, 4-Stage Balance Test, and observation of walking speed and stride variability.
  • A TUG time โ‰ฅ12 seconds identifies increased falls risk; values โ‰ฅ14 seconds indicate high risk and warrant specialist referral or comprehensive geriatric assessment.
  • Medication review is essential โ€” psychotropics (benzodiazepines, antipsychotics, SSRIs), opioids, anticholinergics, antihypertensives and polypharmacy (โ‰ฅ4 medications) independently increase falls risk.
  • Orthostatic hypotension must be assessed with lying-to-standing blood pressure (โ‰ฅ20 mmHg systolic or โ‰ฅ10 mmHg diastolic drop within 3 minutes of standing is diagnostic).
  • Exercise is the single most effective falls prevention intervention โ€” supervised balance training โ‰ฅ3 times per week reduces falls by 23โ€“40%; Tai Chi, Otago Exercise Programme and group-based strength-and-balance programmes have the strongest evidence.
  • Vitamin D supplementation (800โ€“1000 IU/day cholecalciferol) should be considered for older adults who are housebound, institutionalised or have documented deficiency, as it may reduce falls in residential care settings.
  • Home hazard modification by an occupational therapist reduces falls by approximately 20%, particularly when targeted to those at high risk with a history of falls.
  • Falls in hospital and residential aged care require structured risk screening on admission and ongoing reassessment; multi-component inpatient programmes reduce falls by 20โ€“30%.
  • Aboriginal and Torres Strait Islander older adults experience higher rates of falls and fall-related injury with lower access to preventive services โ€” culturally safe, community-based programmes are essential.
  • Fracture risk must be considered in every faller โ€” assess for osteoporosis (FRAX/DXA), ensure adequate calcium and vitamin D, and consider bisphosphonate therapy where indicated.
  • Post-fall assessment should include cardiac evaluation (carotid sinus hypersensitivity, arrhythmia screen) and head-CT if head injury or anticoagulant use, even in the absence of obvious trauma.

Introduction & Australian Epidemiology

Falls are a major geriatric syndrome and the leading cause of injury-related morbidity, mortality and residential aged-care admission in older Australians. They commonly arise from interacting intrinsic factors โ€” including gait impairment, muscle weakness, cognitive decline, sensory deficits and medication effects โ€” and extrinsic risks such as environmental hazards, ill-fitting footwear and acute illness. The dynamic interplay between an individual's physiological reserve and their activity level, environment and exposure to precipitating factors determines whether a fall occurs.

According to the Australian Institute of Health and Welfare (AIHW), falls accounted for over 250,000 hospitalisations in 2021โ€“22, with the age-standardised rate increasing by approximately 3% per year over the past decade. In 2022, falls were the underlying cause of death in approximately 5,400 Australians, making them the leading cause of injury-related death nationally. The direct healthcare cost of falls exceeds .3 billion annually when hospital, emergency department, rehabilitation and aged-care costs are included.

Community-dwelling Australians aged โ‰ฅ65 years experience a falls incidence of approximately 0.6โ€“1.0 falls per person-year; this rises to 1.5 falls per person-year in residential aged care. Approximately 10โ€“15% of falls result in serious injury including hip fracture, other fractures, head injury or joint dislocation. Hip fractures are particularly devastating โ€” with 30-day mortality of 5โ€“10% and 12-month mortality approaching 25โ€“30% โ€” and are a major driver of loss of independence and long-term residential care admission.

โš ๏ธ
One fall is a strong predictor of future falls. An older person who has fallen once has a 2-fold increased risk of falling again within 12 months. A history of โ‰ฅ2 falls or a fall presenting to the emergency department should trigger a comprehensive multifactorial assessment, not simply reassurance.

Key risk factors for falls in Australian older adults include:

  • Intrinsic: Age โ‰ฅ80 years, female sex (for hip fracture), previous falls, gait and balance impairment, muscle weakness (quadriceps), visual impairment, cognitive impairment or dementia, depression, urinary incontinence, orthostatic hypotension, neuropathy (peripheral or autonomic), Parkinson's disease, osteoarthritis, and stroke sequelae.
  • Extrinsic / Environmental: Loose rugs, poor lighting, wet or uneven surfaces, absence of handrails, clutter, inappropriate footwear (slippers, thongs), and inadequate assistive devices.
  • Medication-related: Polypharmacy (โ‰ฅ4 medications), psychotropic agents, opioids, antihypertensives (particularly when recently initiated or dose-changed), and anticholinergic burden.
  • Situational: Rushing to the toilet (urgency incontinence), postprandial hypotension, nocturia, and unfamiliar environments.

Falls Risk Assessment

A comprehensive, multifactorial falls risk assessment is recommended for all older adults who present with a fall, report recurrent falls or demonstrate gait and balance impairment. The assessment should be performed by the general practitioner in primary care, with referral to a geriatrician, physiotherapist or falls clinic as indicated. The Royal Australian College of General Practitioners (RACGP) and the Australian Commission on Safety and Quality in Health Care (ACSQHC) recommend a structured approach aligned with the 45+ Health Check and annual over-75 assessments.

When to Screen

  • All adults aged โ‰ฅ65 years should be asked about falls at least annually.
  • Any presentation with a fall (including unwitnessed falls or "found on floor") requires a systematic assessment.
  • Patients reporting loss of balance, near-falls ("stumbles") or fear of falling should be assessed even without a reported fall.
  • Reassessment at every change in functional status, after hospitalisation, on medication change, or on transition to residential aged care.

Components of the Multifactorial Assessment

Domain Assessment Red Flags / Action Thresholds
Fall history Circumstances, frequency, injury, lying time, witness accounts โ‰ฅ2 falls in 12 months; unexplained falls; loss of consciousness preceding fall
Gait, balance & mobility TUG, 30-Second Chair Stand, 4-Stage Balance Test, Tinetti, DGI TUG โ‰ฅ12 s; Chair Stand <5 reps; unable to hold tandem stance 10 s
Muscle strength Hand-held dynamometry; 30-Second Chair Stand; quadriceps testing Chair Stand <5 reps; grip strength below age-sex norms
Vision Visual acuity (Snellen chart), visual fields, cataract screening VA worse than 6/12; visual field defect; diplopia
Cognition MMSE, MoCA, GP assessment of cognitive tool (GPCOG) Impaired executive function or attention increasing fall risk; delirium screen
Medications Medication count, high-risk drug classes, anticholinergic burden, recent changes โ‰ฅ4 medications; psychotropics; opioids; anticholinergic burden scale score โ‰ฅ3
Orthostatic hypotension Lying and standing BP at 1 and 3 minutes; symptoms on standing โ‰ฅ20/10 mmHg drop or symptomatic
Continence Bladder diary, urgency, nocturia episodes, pad use โ‰ฅ2 nocturia episodes; urgency incontinence; rushing to toilet
Feet & footwear Foot inspection, proprioception, appropriate shoe assessment Peripheral neuropathy; ill-fitting shoes; walking in socks or barefoot
Home environment OT home assessment; hazards checklist; assistive device evaluation Loose rugs, poor lighting, no grab rails, steep stairs, wet areas
Fear of falling Falls Efficacy Scaleโ€“International (FES-I) High FES-I score; activity restriction due to fear
Nutrition MNA-SF, weight, albumin, vitamin D level BMI <22; unintentional weight loss; 25(OH)D <50 nmol/L

Screening Tools in Primary Care

For rapid screening in time-limited consultations, the following approach is recommended:

1
Ask about falls
"Have you fallen in the past 12 months? Are you worried about falling?" If yes to either, proceed to step 2.
2
Perform TUG test
Timed Up and Go โ€” patient rises from armchair, walks 3 m, turns, walks back, sits. Normal <10 s; borderline 10โ€“12 s; abnormal โ‰ฅ12 s.
3
Check orthostatic BP
Measure lying (5 min rest) and standing BP at 1 and 3 minutes. Document symptoms.
4
Review medications
Count medications. Identify high-risk drugs. Consider deprescribing where safe.
5
Refer for comprehensive assessment
Physiotherapy for balance and strength, occupational therapy for home assessment, falls clinic or geriatrician if complex or recurrent falls.

Gait and Balance Examination

Gait and balance assessment is the single most informative component of the falls evaluation. Abnormalities in gait โ€” including reduced speed, widened base, shortened stride, increased variability and asymmetric arm swing โ€” are independent predictors of falls, disability, cognitive decline and mortality in older adults. In Australian primary care, gait assessment can be performed rapidly with simple validated tools requiring minimal equipment.

Systematic Approach to Gait Observation

Observe the patient walking at their comfortable pace for at least 10 metres in a well-lit corridor. Note the following features:

  • Initiation: Hesitancy or freezing at start suggests Parkinson's disease, normal pressure hydrocephalus or frontal lobe pathology.
  • Speed: Normal gait speed in healthy older adults is 1.0โ€“1.3 m/s. Speed <0.8 m/s is associated with increased falls risk, disability and mortality; <0.6 m/s indicates severe mobility impairment.
  • Stride length and symmetry: Shortened stride suggests deconditioning, fear, arthritis, or neurodegeneration. Asymmetry suggests stroke, unilateral joint disease or pain.
  • Base width: Widened base (>10 cm heel-to-heel) indicates cerebellar disease, vestibular loss or proprioceptive deficit.
  • Cadence and rhythm: Irregular cadence or festination suggests Parkinson's disease. Steppage gait suggests foot drop (peroneal neuropathy, L5 radiculopathy, peripheral neuropathy).
  • Arm swing: Reduced unilateral arm swing suggests Parkinson's disease. Bilateral reduction may be deconditioning or Parkinsonism.
  • Trunk stability and posture: Lateral trunk lean, kyphosis, and inability to maintain upright posture during turning increase falls risk.
  • Turning: Multi-step turns (>3 steps) or instability during turning are predictive of falls. The "Turn 180ยฐ" test is a simple screen.

Validated Assessment Tools

Tool What It Measures Cut-off / Scoring Setting
Timed Up and Go (TUG) Functional mobility โ€” sit to stand, walk 3 m, turn, return <10 s = normal; 10โ€“12 s = borderline; โ‰ฅ12 s = increased risk; โ‰ฅ14 s = high risk Primary care, ward, clinic
30-Second Chair Stand Lower limb strength and endurance Age-sex norms; <5 repetitions = high risk for falls Primary care, community
4-Stage Balance Test Static balance โ€” parallel stance, semi-tandem, tandem, single leg Unable to hold tandem stance โ‰ฅ10 s = increased falls risk Primary care, community
Tinetti POMA Gait (12 items) and balance (9 items); total /28 <19 = high falls risk; 19โ€“24 = moderate risk Clinic, inpatient, research
Dynamic Gait Index (DGI) Dynamic balance during functional tasks (8 items, /24) <19/24 = increased falls risk Physiotherapy, falls clinic
Functional Reach Test Limits of stability โ€” forward reach distance <25 cm = high risk; <15 cm = very high risk Primary care, clinic
10-Metre Walk Test Gait speed at comfortable and fast pace <0.8 m/s (comfortable) = falls and disability risk Primary care, rehab
DGI abbreviated / GaitSpeed Quick screen โ€” "6th vital sign" Age โ‰ฅ65 with gait speed <1.0 m/s warrants further assessment Any setting

Gait Patterns and Clinical Correlation

Gait Pattern Features Suggests
Antalgic Shortened stance phase on affected side, pain-limited Osteoarthritis (hip/knee), fracture, peripheral vascular disease
Shuffling / Festinating Short shuffling steps, stooped posture, reduced arm swing, acceleration Parkinson's disease, Parkinsonism
Steppage / High-stepping Exaggerated hip and knee flexion to clear foot; foot slaps ground Foot drop โ€” peroneal neuropathy, L5 radiculopathy, peripheral neuropathy
Ataxic / Wide-based Wide base, irregular, lurching, difficulty with tandem walking Cerebellar disease, alcohol, posterior fossa pathology
Waddling Lateral trunk lean, Trendelenburg sign, pelvic drop Hip abductor weakness โ€” myopathy, hip osteoarthritis, lumbar stenosis
Senile / Cautious Wide base, short stride, arms forward for balance, slow speed Deconditioning, fear of falling, multi-sensory deficit
Magnetic / Apraxic Feet seem "glued" to floor, difficulty lifting feet, poor initiation Normal pressure hydrocephalus, frontal lobe disease, bilateral MCA stroke
Hemiplegic Circumduction of affected leg, stiff arm, unilateral pattern Stroke, intracranial pathology
โ„น๏ธ
Gait speed as the "6th vital sign": Measuring comfortable gait speed over 4โ€“6 metres is a simple, rapid and highly informative functional test. Speed <0.8 m/s in an older adult predicts falls, disability, hospitalisation and mortality. It can be incorporated into routine clinical encounters with no special equipment โ€” only a measured corridor and a stopwatch.

Vestibular and Proprioceptive Assessment

  • Romberg test: Eyes-open then eyes-closed on firm surface. Loss of balance with eyes closed suggests proprioceptive or vestibular deficit. Duration <30 s is abnormal.
  • Untersberger (Fukuda) stepping test: Patient marches on the spot with eyes closed for 50 steps. Rotation >30ยฐ or lateral displacement >1 m suggests unilateral vestibular lesion.
  • Head impulse test: Assess vestibulo-ocular reflex. Corrective saccade indicates peripheral vestibular deficit. Refer for formal vestibular assessment if positive.
  • Sensory Organization Test: Formal posturography (available at specialist balance centres) can differentiate sensory vs motor contributions to balance impairment.

Medication and Orthostatic Review

Medications are one of the most modifiable risk factors for falls in older Australians. Polypharmacy โ€” commonly defined as โ‰ฅ4 regular medications โ€” and specific drug classes independently increase falls risk through mechanisms including sedation, orthostatic hypotension, impaired cognition, blurred vision, muscle weakness and prolongation of reaction time. A structured medication review should be performed for every older person who falls or is at risk of falling.

High-Risk Medication Classes

Drug Class Mechanism of Falls Risk Relative Risk Action
Benzodiazepines Sedation, impaired coordination, cognitive impairment OR 1.5โ€“2.0 Gradual taper and cease; if essential, short-acting agents only (oxazepam)
SSRIs / SNRIs Orthostatic hypotension, sedation, hyponatraemia, serotonin effects on balance OR 1.5โ€“1.7 Review indication; consider dose reduction or switching; monitor sodium
Antipsychotics Sedation, extrapyramidal effects, orthostatic hypotension, QTc prolongation OR 1.5โ€“2.0 Deprescribe if prescribed for behavioural symptoms of dementia; seek specialist advice
Opioids Sedation, dizziness, constipation-related urgency, myoclonus OR 1.5โ€“2.0 Minimise dose; use paracetamol and non-pharmacological strategies first; review regularly
Antihypertensives Orthostatic hypotension, excessive blood pressure lowering OR 1.2โ€“1.4 Review BP targets in elderly (150/90 acceptable for โ‰ฅ80 yrs); avoid aggressive titration
Diuretics Dehydration, electrolyte disturbance, nocturia, urgency OR 1.2โ€“1.4 Review indication; monitor electrolytes; consider timing to reduce nocturia
Anticholinergics Sedation, blurred vision, cognitive impairment, urinary retention OR 1.2โ€“1.5 Calculate anticholinergic burden score; deprescribe agents with high burden
Anticonvulsants Sedation, ataxia, cognitive impairment, osteomalacia OR 1.5โ€“1.9 Minimise dose; review indication for gabapentinoids; monitor vitamin D
Hypnotics (Z-drugs) Sedation, nocturnal confusion, impaired nocturnal coordination OR 1.5โ€“2.0 Deprescribe; use sleep hygiene strategies; short course only if essential
๐Ÿšจ
Central nervous system (CNS) polypharmacy โ€” the concurrent use of โ‰ฅ3 CNS-active medications (benzodiazepines, opioids, antidepressants, antipsychotics, anticonvulsants) โ€” confers a particularly high falls risk (OR 2.5โ€“3.5). This combination is increasingly common in residential aged care and warrants urgent medication review.

Orthostatic Hypotension

Orthostatic hypotension (OH) is defined as a sustained reduction in systolic blood pressure โ‰ฅ20 mmHg or diastolic blood pressure โ‰ฅ10 mmHg within 3 minutes of standing from a supine position. It affects 15โ€“30% of community-dwelling older adults and up to 50% of those in residential aged care. OH is an independent risk factor for falls, syncope, fractures, cardiovascular events and mortality.

Measurement Technique

  • Patient rests supine for โ‰ฅ5 minutes (ideally 10 minutes) in a quiet room.
  • Record supine BP (average of 2 readings), heart rate, and any symptoms.
  • Patient stands (with assistance if needed). Record standing BP and HR at 1 minute and 3 minutes.
  • Document symptoms: dizziness, lightheadedness, visual blurring, weakness, palpitations, neck/shoulder "coat-hanger" pain.
  • A positive result = โ‰ฅ20/10 mmHg drop OR symptoms on standing.

Causes and Contributing Factors

Medication Causes
  • Antihypertensives (all classes)
  • Diuretics
  • Alpha-blockers (tamsulosin, prazosin)
  • Nitrates
  • Tricyclic antidepressants
  • Antipsychotics (especially clozapine, quetiapine)
  • Levodopa / dopamine agonists
  • Sildenafil and PDE-5 inhibitors
Non-Medication Causes
  • Dehydration / hypovolaemia
  • Autonomic neuropathy (diabetes, Parkinson's, amyloidosis)
  • Adrenal insufficiency
  • Anaemia
  • Prolonged bed rest / deconditioning
  • Venous insufficiency / varicosities
  • Postprandial hypotension
  • Age-related baroreflex decline

Management of Orthostatic Hypotension

๐Ÿ’Š
Midodrine
Gutronยฎ ยท Alpha-1 adrenergic agonist
Adult dose 2.5โ€“5 mg PO TDS (morning, midday, late afternoon); max 10 mg TDS; avoid dosing after 6 PM
Renal adjustment No specific adjustment; use with caution in renal impairment
Key considerations Monitor supine BP; contraindicated in supine hypertension (>180/110); avoid in urinary retention and severe cardiac disease
PBS status Authority Required
๐Ÿ’Š
Fludrocortisone
Florinefยฎ ยท Mineralocorticoid
Adult dose 50โ€“200 mcg PO daily (start 50 mcg, titrate over 1โ€“2 weeks)
Renal adjustment Use with caution; monitor potassium and fluid balance closely
Key considerations May worsen supine hypertension; monitor for oedema, hypokalaemia, headache; avoid in heart failure
PBS status PBS General Benefit

Non-Pharmacological Measures for Orthostatic Hypotension

  • Slow positional changes โ€” sit at edge of bed for 2 minutes before standing; stand for 2 minutes before walking.
  • Adequate hydration โ€” aim for 1.5โ€“2.5 L/day fluid intake (adjusted for cardiac/renal status).
  • Increase salt intake to 6โ€“10 g NaCl/day if no contraindication (heart failure, hypertension, renal disease).
  • Compression stockings (thigh-high, 20โ€“30 mmHg) โ€” effective but compliance is often poor; abdominal compression garments may be better tolerated.
  • Physical counter-maneuvers: leg crossing, squatting, muscle tensing before standing.
  • Head-of-bed elevation 10โ€“15ยฐ to reduce supine hypertension and nocturnal pressure natriuresis.
  • Avoid triggers: hot environments, large meals, alcohol, prolonged standing, straining at stool.
  • Review and adjust medication timing โ€” give antihypertensives at night rather than morning where safe to do so.

Deprescribing Principles

Deprescribing should be a structured, patient-centred process using shared decision-making. The following approach is recommended:

1
Comprehensive medication reconciliation
Review all medications including OTC, supplements, and complementary medicines. Use the PBS My Health Record medicines list and community pharmacy records.
2
Identify high-risk and potentially inappropriate medications
Apply STOPP/START criteria (v2), Beers Criteria, and anticholinergic burden scale (Anticholinergic Cognitive Burden Scale).
3
Prioritise and plan tapering
Taper one medication at a time. Start with the highest-risk agent. Allow 2โ€“4 weeks between dose reductions. Use dose-reduction schedules (e.g., benzodiazepine taper over 8โ€“12 weeks).
4
Monitor and follow up
Review within 2โ€“4 weeks of each change. Monitor for withdrawal effects, disease recurrence, and functional improvement. Document goals and outcome.

Prevention, Exercise and Rehabilitation

Falls prevention requires a multifaceted approach targeting the individual risk factors identified during assessment. Systematic reviews and meta-analyses (including the 2019 Cochrane review by Sherrington et al.) have established that exercise โ€” particularly programmes emphasising balance training โ€” reduces the rate of falls by 23% in community-dwelling older adults and up to 34% in those with Parkinson's disease. When combined with medication review, home modification and vision correction, the cumulative effect is greater.

Evidence-Based Exercise Programmes

Community
Group Strength & Balance Classes
Tai Chi, gentle exercise groups, and community strength-and-balance classes. Minimum 2 sessions/week (ideally 3). Focus on challenging balance (reducing base of support, moving centre of mass, single-leg standing, stepping exercises).
Setting: community centre, council-run programmes, local PCYC
Individual
Otago Exercise Programme
Home-based individually prescribed programme of progressive strength (ankle dorsiflexors, knee extensors, hip abductors/extensors) and balance exercises. 5ร—/week with 5 physiotherapy visits over 12 months. Falls reduction of 35% in those aged โ‰ฅ80. Available through Australian physiotherapy services.
Setting: home-based; prescribed by physiotherapist; funded via Medicare (EPC items 10950โ€“10970)
Specialist
Falls Prevention Clinic / Geriatrician-Led Programme
Comprehensive multidisciplinary assessment with physiotherapy, OT, geriatrician, pharmacy. Indicated for recurrent falls, complex comorbidities, falls with injury, or failure of community programmes. Includes neurophysiology, vestibular rehab, cardiac investigation.
Setting: hospital outpatient; referral via GP or emergency department

Exercise Prescription Principles

  • Balance training must be the core component โ€” static balance (standing with reduced support) and dynamic balance (walking with direction changes, obstacles, dual-tasking). The exercise must challenge balance to be effective.
  • Progressive resistance training โ€” targeting lower limb extensors, ankle dorsiflexors and hip abductors. Use body weight, resistance bands or weights. Aim for 2โ€“3 sets of 8โ€“12 repetitions at moderate intensity (RPE 5โ€“6/10).
  • Frequency: Minimum 2 hours per week of balance and strength training; optimal 3โ€“5 sessions per week. "More is better" โ€” dose-response relationship is well established.
  • Intensity: The balance challenge must be sufficient to cause some instability (within safe limits). Simply walking or standing is not sufficient โ€” exercises must be performed near the limits of stability.
  • Duration: Benefits are maintained only while exercising continues. Programmes should be lifelong or at minimum ongoing. Encourage transition from supervised to self-directed exercise.
  • Adherence: Intrinsic motivation, enjoyment, social engagement and perceived benefit are the strongest predictors of adherence. Group programmes tend to have better long-term adherence than home programmes.
โœ…
Tai Chi has Level I evidence for falls prevention, with a meta-analytic falls rate reduction of approximately 20%. It improves balance, strength, proprioception, reaction time and fear of falling. Multiple Australian community programmes are available through local councils and community health services.

Home Hazard Modification

Occupational therapy-delivered home hazard assessment and modification is an evidence-based intervention, particularly effective when targeted to those at high risk (history of โ‰ฅ1 fall, recent hospital discharge). The OT assesses and addresses environmental hazards and prescribes assistive devices.

Hazard Modification Priority
Loose rugs, mats, cords Remove or secure with non-slip backing/tape High
Poor lighting (especially hallways, stairs, bathrooms) Install night lights, sensor lights, increase wattage, improve switch access High
Wet/slippery bathroom surfaces Non-slip mat in shower/bath; grab rails at shower, toilet and bath; consider shower chair High
Stairs without handrails Install handrails on both sides; ensure stair nosings are visible; non-slip treads High
Clutter, furniture obstructing pathways Clear pathways; rearrange furniture; remove low objects Medium
Inadequate outdoor lighting Sensor lights at entries; improve garden path surfaces Medium
Steep or uneven steps/paths Ramp installation; handrails; path repair; consider alternative entry route Medium

Assistive Devices

  • Walking aids: Walking sticks (single-point or quad stick), rollator frames, and walking frames should be individually assessed and fitted by a physiotherapist. An incorrectly fitted or inappropriate walking aid can increase falls risk. Review regularly.
  • Hip protectors: Evidence for hip protectors is mixed. May be considered for high-risk individuals in residential aged care (where compliance can be supported), but are not recommended as a primary prevention strategy.
  • Personal alarm systems: Wearable alarms or medical alert devices can reduce lying time after a fall. Recommended for those living alone with recurrent falls risk. Available through community support services and Commonwealth Home Support Programme (CHSP).
  • Footwear assessment: Recommend firm, low-heeled shoes with non-slip soles and secure fastening (lace-up or Velcro). Avoid thongs, loose slippers, high heels and walking in socks or barefoot on hard surfaces.

Vision Correction

  • Annual optometry review for all older adults at risk of falls (Medicare-funded for โ‰ฅ65 years).
  • Cataract surgery reduces falls by approximately 34% โ€” refer for cataract assessment when visual impairment contributes to falls risk.
  • Multifocal and progressive lenses may increase falls risk due to peripheral distortion โ€” consider single-vision distance glasses for outdoor walking and bifocals only for indoor use.
  • Avoid new multifocal prescription when hospitalised or in unfamiliar environments.

Vitamin D Supplementation

๐Ÿ’Š
Cholecalciferol (Vitamin Dโ‚ƒ)
Ostelinยฎ, various generic ยท Vitamin supplement
Indication Housebound older adults, residential aged care residents, documented 25(OH)D <50 nmol/L
Dose for falls prevention 800โ€“1000 IU (20โ€“25 mcg) PO daily; loading dose of 50,000 IU weekly ร— 6โ€“10 weeks if severely deficient (<25 nmol/L), then maintenance
Renal adjustment CKD Stage 4โ€“5: use calcitriol or alfacalcidol under nephrology guidance; monitor calcium and phosphate
Key considerations May reduce falls in residential aged care (Level I evidence); effect in community-dwelling adults with adequate vitamin D is minimal. Combine with calcium if osteoporosis co-exists.
PBS status Not PBS (OTC supplement)

Cardiac and Syncope Evaluation

For unexplained falls, recurrent falls or falls with features suggesting loss of consciousness, cardiac evaluation is essential:

  • 12-lead ECG โ€” assess for arrhythmia, conduction disease, QTc prolongation, ischaemic changes.
  • Carotid sinus massage (under continuous cardiac monitoring) โ€” carotid sinus hypersensitivity causes up to 35% of unexplained falls in older adults; diagnosis requires โ‰ฅ3 second asystole or โ‰ฅ50 mmHg systolic drop. Refer to cardiology for consideration of dual-chamber pacemaker if symptomatic.
  • Holter monitor / event recorder / implantable loop recorder โ€” for suspected arrhythmic syncope or unexplained falls with negative initial workup.
  • Echocardiography โ€” if structural heart disease suspected (murmur, heart failure signs, ECG abnormalities).
  • Active standing test / tilt table test โ€” for suspected vasovagal syncope or autonomic dysfunction causing unexplained falls.
โš ๏ธ
In-hospital falls prevention: All Australian hospitals must have a falls prevention programme as part of NSQHS Standards (Standard 5). Interventions include admission risk screening (STRATIFY or FRAT), bed/chair alarms, low beds, non-slip footwear, supervised mobilisation, medication review and toileting programmes. Inpatient falls prevention reduces falls by 20โ€“30%.

Post-Fall Management Algorithm

1
Immediate assessment
Assess for injury (fracture, head injury, soft tissue). Check for anticoagulant use โ€” if on warfarin/DOAC with head strike, CT head regardless of symptoms. Assess for loss of consciousness. Check neurological status.
2
Investigate cause
Detailed history of circumstances. Orthostatic BP. ECG. Bloods (FBC, UEC, glucose, calcium, vitamin D, TSH, B12). Medication review. Cognitive screen if not already assessed.
3
Multifactorial intervention
Address modifiable risks: exercise programme, medication adjustment, vision/footwear/home modification, orthostatic management, continence treatment, vitamin D, fracture risk assessment.
4
Follow-up and monitoring
GP review at 2โ€“4 weeks. Physiotherapy/OT within 1โ€“2 weeks. Reassess in 3 months. Ongoing annual falls risk review. Consider referral to falls clinic if recurrent or complex.

Fracture Risk Assessment

Every older person who falls should have their fracture risk assessed. Falls and osteoporosis are independent but synergistic risk factors for fracture. Assessment and management includes:

  • FRAX (Fracture Risk Assessment Tool) โ€” 10-year probability of major osteoporotic fracture and hip fracture. Australian-specific thresholds for DXA referral and treatment initiation apply.
  • DXA (Dual-energy X-ray Absorptiometry) โ€” indicated when FRAX suggests high risk, or when a minimal-trauma fracture has occurred (MBS item 12320).
  • Calcium and vitamin D adequacy โ€” ensure dietary calcium โ‰ฅ1300 mg/day (supplement if dietary intake insufficient) and 25(OH)D โ‰ฅ50 nmol/L.
  • Anti-osteoporosis therapy โ€” bisphosphonates (alendronate, risedronate), denosumab, or teriparatide as indicated per PBS criteria. For patients with minimal-trauma fracture presenting via ED, the Australian Fracture Liaison Service model recommends initiating treatment before discharge or at 6-week follow-up.

Special Populations

๐Ÿ‘ด

Elderly (โ‰ฅ80 years)

Falls incidence: 50% per year; multiple falls in 15โ€“20%.
Key considerations: Sarcopenia, frailty, multi-morbidity, polypharmacy and sensory decline are highly prevalent. Comprehensive geriatric assessment is strongly recommended.
BP targets: Relaxed targets (systolic 140โ€“150 mmHg) are appropriate if falls and orthostatic symptoms are present. Avoid over-treatment of hypertension.
Cognitive considerations: Patients with dementia have 2โ€“3ร— the falls risk. Supervised exercise and environmental modification are critical. Ensure wandering risks are assessed (e.g., door alarms in residential care).
Residential aged care: Over 50% of residents fall annually. Structured falls programmes with physiotherapy, vitamin D, medication review, hip protectors (where acceptable), and bed/low-height interventions are recommended.
๐Ÿ‘ถ

Paediatrics

Not applicable for this topic: Falls in children are developmentally normal and differ fundamentally from geriatric falls in aetiology and management.
Exception โ€” childhood falls as cause of injury: Paediatric falls (playground, home) are the leading cause of childhood injury presentations to Australian EDs. Prevention focuses on environmental safety (window guards, playground surfacing, supervision).
๐Ÿซ˜

Renal Impairment

Increased risk: CKD stages 3bโ€“5 independently increases falls risk through anaemia, electrolyte disturbance (hypokalaemia, hypomagnesaemia), acidosis, uraemic neuropathy, bone-mineral disorder and polypharmacy.
Vitamin D: CKD stages 4โ€“5 require active vitamin D metabolites (calcitriol or alfacalcidol) rather than cholecalciferol; use under nephrology guidance. Monitor calcium and phosphate closely.
Antihypertensives: Dialysis patients experience intradialytic hypotension โ€” review antihypertensives in the context of dialysis schedules; avoid pre-dialysis dosing.
Drug dose adjustments: Renal drug clearance alterations increase side-effect risk for many falls-related medications (gabapentin, opioids, lithium, digoxin). Refer to renal drug dosing guidelines.
๐Ÿซ

Hepatic Impairment

Increased risk: Hepatic encephalopathy, coagulopathy (increased bleeding risk post-fall), muscle wasting (sarcopenia of cirrhosis), and altered drug metabolism.
Benzodiazepines: Avoid or use with extreme caution โ€” prolonged half-life, increased sedation. If essential for alcohol withdrawal management, use short-acting agents and monitor closely.
Fracture risk: Osteoporosis is common in chronic liver disease (particularly cholestatic and alcohol-related). Ensure DXA assessment and appropriate anti-osteoporosis treatment.
Paracetamol: Safe at โ‰ค2 g/day in compensated cirrhosis; avoid exceeding recommended doses. NSAIDs are contraindicated.
๐Ÿ›ก๏ธ

Immunocompromised

Increased risk: Immunosuppressant medications (corticosteroids, tacrolimus, cyclosporine) contribute to falls through myopathy, neuropathy, glucose disturbance and osteoporosis.
Corticosteroid-induced osteoporosis: Prolonged prednisolone โ‰ฅ7.5 mg/day for โ‰ฅ3 months increases fracture risk independently of falls. DXA and bisphosphonate initiation per PBS criteria (alendronate 70 mg weekly or risedronate 35 mg weekly; PBS General Benefit for steroid-induced osteoporosis).
Infection risk: Fracture-related immobility increases risk of hospital-acquired infections (pneumonia, UTI, pressure injuries) in immunocompromised patients.
๐Ÿคฐ

Pregnancy

Not applicable for the primary target population: This article focuses on geriatric falls (age โ‰ฅ65 years).
Note: Falls in pregnancy relate to altered centre of gravity, laxity of ligaments and are managed differently. Refer to obstetric guidelines.
Aboriginal and Torres Strait Islander Health
Epidemiology
Aboriginal and Torres Strait Islander Australians experience falls-related hospitalisations at approximately 1.5โ€“2 times the rate of non-Indigenous Australians, with higher rates of hip fracture and fall-related head injury. The burden is particularly high in older adults aged โ‰ฅ50 years, reflecting the earlier onset of chronic disease and multimorbidity in Indigenous populations (AIHW 2023).
Earlier onset of risk factors
Chronic diseases that increase falls risk โ€” including diabetes (peripheral and autonomic neuropathy), renal disease, cardiovascular disease and cognitive impairment โ€” have an earlier onset (by approximately 10โ€“15 years) in Aboriginal and Torres Strait Islander populations. Falls risk assessment should commence at age โ‰ฅ50 years rather than โ‰ฅ65 years.
Remote and very remote access
Many Aboriginal and Torres Strait Islander older adults live in remote or very remote communities where access to physiotherapy, occupational therapy, falls clinics, geriatricians, optometry and podiatry is extremely limited or non-existent. Telehealth, fly-in-fly-out (FIFO) specialist services, and training of Aboriginal and Torres Strait Islander health workers in falls risk screening are essential strategies.
Cultural safety
Falls prevention programmes must be culturally safe, community-led and delivered in partnership with Aboriginal Community Controlled Health Organisations (ACCHOs). Exercise programmes should incorporate culturally relevant activities (e.g., traditional dance, community walking groups, modified Otago programmes co-designed with Elders). Fear of institutional care and historical distrust of health services may reduce engagement โ€” programmes must be built on trust and self-determination.
Environmental and housing factors
Overcrowded housing, inadequate lighting, lack of handrails and bathroom modifications, uneven ground surfaces, and limited access to assistive devices are common in remote Indigenous communities. Home modification programmes require specific funding and engagement with housing agencies. Commonwealth-funded Home Modifications Program and National Aboriginal and Torres Strait Islander Housing initiatives can be leveraged.
Medication management
Polypharmacy and psychotropic medication use (particularly antipsychotics and benzodiazepines) contribute to falls risk. Medication review through the MBS Indigenous Health Incentive (Practice Incentives Program) and Remote Area Aboriginal Health Services (RAAHS) should be actively utilised. Medication management reviews (Home Medicines Review, MBS item 900) can be conducted by visiting pharmacists in remote communities.
Vitamin D and nutrition
Despite higher sun exposure, vitamin D deficiency occurs in some Aboriginal and Torres Strait Islander populations due to indoor lifestyle, chronic disease and malnutrition. Food insecurity contributes to inadequate calcium and protein intake, increasing sarcopenia and fracture risk. Address through community nutrition programmes and targeted supplementation.
National frameworks
Align falls prevention with the National Aboriginal and Torres Strait Islander Aged Care Strategy, the Closing the Gap targets (particularly Outcome Area 1 โ€” health and Outcome Area 4 โ€” social determinants), and RHDAustralia clinical guidelines for chronic disease management. The AIHW Indigenous-specific falls data reports and the Lowitja Institute research on Indigenous ageing provide evidence for programme development.

๐Ÿ“š References

  1. 1. Sherrington C, Fairhall NJ, Wallbank GK, et al. Exercise for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2019;1(1):CD012424.
  2. 2. Australian Institute of Health and Welfare (AIHW). Falls in older Australians 2019โ€“20: hospitalisations and deaths among people aged 65 and over. AIHW; 2023.
  3. 3. Panel on Prevention of Falls in Older Persons, American Geriatrics Society and British Geriatrics Society. Summary of the Updated American Geriatrics Society/British Geriatrics Society Clinical Practice Guideline for Prevention of Falls in Older Persons. J Am Geriatr Soc. 2011;59(1):148โ€“157.
  4. 4. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th ed. Melbourne: RACGP; 2016 (updated 2018). Chapter 11: Falls prevention in older people.
  5. 5. Australian Commission on Safety and Quality in Health Care (ACSQHC). Safety and Quality Improvement Guide Standard 5: Comprehensive Care โ€” Preventing Falls and Harm from Falls. Sydney: ACSQHC; 2021.
  6. 6. O'Mahony D, O'Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213โ€“218.
  7. 7. Thomas S, Mackintosh S, Halbert J. Does the 'Otago exercise programme' reduce mortality and falls in older adults?: a systematic review and meta-analysis. Age Ageing. 2010;39(6):681โ€“687.
  8. 8. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012;(9):CD007146.
  9. 9. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69โ€“72.
  10. 10. Australian Institute of Health and Welfare (AIHW). The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples. AIHW; 2023.
  11. 11. National Health and Medical Research Council (NHMRC). Australian guidelines to reduce health risks from drinking alcohol. Canberra: NHMRC; 2020. [Relevant for alcohol-related falls risk.]
  12. 12. Hosseini SR, Cumming RG, Kheirkhah F, et al. The association between polypharmacy and falls in older adults: a systematic review and meta-analysis. Drugs Aging. 2024;41(1):21โ€“35.
  13. 13. Lord SR, Sherrington C, Menz HB, Close JCT. Falls in older people: risk factors and strategies for prevention. 3rd ed. Cambridge: Cambridge University Press; 2021.
  14. 14. Logan PA, Armstrong S, Birtles T, et al. Occupational therapy home assessment and modification for older adults at risk of falls: a systematic review and meta-analysis. Age Ageing. 2023;52(8):afad147.
  15. 15. Royal Australian and New Zealand College of Psychiatrists (RANZCP). Practice guideline for deprescribing benzodiazepines and Z-drugs. Melbourne: RANZCP; 2023.
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ยฑ NSAID; manual therapy
2โ€“6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ยฑ calcitonin; DXA + osteoporosis Rx
6โ€“12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ยฑ morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

๐Ÿ“š References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760โ€“765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60โ€“75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395โ€“403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581โ€“E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112โ€“120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144โ€“153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805โ€“811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3โ€“4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

๐Ÿ“š References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924โ€“939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736โ€“745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583โ€“1599.
  5. 5. Smolen JS, Landewรฉ RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3โ€“18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487โ€“1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing โ€” misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Associationโ€“European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771โ€“1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFฮฑ blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155โ€“158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3โ€“4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

๐Ÿ“š References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924โ€“939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736โ€“745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583โ€“1599.
  5. 5. Smolen JS, Landewรฉ RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3โ€“18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487โ€“1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing โ€” misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Associationโ€“European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771โ€“1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFฮฑ blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155โ€“158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).